Search Within

GME, Medicine

Formats
  1. Meeting Abstract (757)
  2. Journal Article (571)
  3. Review (146)
  4. Editorial (65)
  5. Research Letter (61)
  6. Correspondence (24)
  7. Guidelines (6)
  8. Miscellaneous (6)
  9. Book Section (5)
  10. Conference Paper (4)
Groups
  1. Graduate Medical Education (1645)
  2. Department of Medicine (1296)
  3. Hematology-Oncology Fellows (1096)
  4. Hematologic Malignancies, Division of (779)
  5. Solid Tumor Oncology Division (649)
  6. Weinberg Fellows (623)

More Groups

People
  1. Gunjan Shah (156)
  2. Kylee Maclachlan (155)
  3. Michael Scordo (148)
  4. Saad Usmani (136)
  5. Sergio Giralt (134)
  6. Alexander Lesokhin (120)

More People

Years
  1. 2025 (173)
  2. 2024 (426)
  3. 2023 (404)
  4. 2022 (323)
  5. 2021 (154)
  6. 2020 (73)

More Years

Publications
  1. Blood (311)
  2. Journal of Clinical Oncology (234)
  3. Clinical Lymphoma, Myeloma and Leukemia (46)
  4. Clinical Cancer Research (43)
  5. Annals of Oncology (37)
  6. Blood Advances (34)

More Publications

Publishers
  1. American Society of Hematology (350)
  2. American Society of Clinical Oncology (272)
  3. Elsevier Inc. (206)
  4. Nature Publishing Group (112)
  5. American Association for Cancer Research (101)
  6. Oxford University Press (70)

More Publishers

Results (1645)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase II study of the menin inhibitor revumenib in leukemia associated with upregulation of HOX genes: Trial in progress
    Meeting Abstract

    Issa, G. C.; Chin, K. K.; Blachly, J. S.; Farhat, A.; Xiao, L.; Ning, J.; Cuglievan, B.; Shukla, N.; Sasaki, K.; Loghavi, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis
    Meeting Abstract

    Blaney, P.; Maclachlan, K. H.; Papadimitriou, M.; Mikulasova, A.; Gagler, D. C.; Braunstein, M. J.; Lahoud, O. B.; Kaminetzky, D.; Wang, Y.; Liu, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR T-cell therapy for DLBCL with CNS involvement: Overall safe and effective with limited efficacy in patients with leptomeningeal disease
    Meeting Abstract

    Luttwak, E.; Cassanello, G.; Brown, S.; Devlin, S. M.; Imber, B. S.; Ip, A.; Leslie, L. A.; Accav, N. G.; Beyar-Katz, O.; Corona, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • NGS MRD negativity on day 28 after brexu cel in adults with R/R ALL is associated with favorable progression free survival
    Meeting Abstract

    Valtis, Y. K.; Nemirovsky, D.; Devlin, S. M.; Roloff, G. W.; Aldoss, I.; Jeyakumar, N.; Miller, K.; Zhang, A.; Sutherland, K. C.; Advani, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save